Expression of MAGE-A and NY-ESO-1 cancer/testis antigens is enriched in triple-negative invasive breast cancers-Reference-Cited by-同舟云学术

Expression of MAGE-A and NY-ESO-1 cancer/testis antigens is enriched in triple-negative invasive breast cancers

Published:2018-04-14 Issue:1 Volume:73 Page:68-80
ISSN:0309-0167
Container-title:Histopathology
language:en
Short-container-title:Histopathology

Author:

Raghavendra Ashwini¹²,Kalita-de Croft Priyakshi¹²^ORCID,Vargas Ana C¹²^ORCID,Smart Chanel E¹²,Simpson Peter T¹²,Saunus Jodi M¹²^ORCID,Lakhani Sunil R¹³

Affiliation:

1. Faculty of Medicine; The University of Queensland; The Royal Brisbane and Women's Hospital; Herston Queensland Australia

2. QIMR Berghofer Medical Research Institute; The Royal Brisbane and Women's Hospital; Herston Queensland Australia

3. Pathology Queensland; The Royal Brisbane and Women's Hospital; Herston Queensland Australia

Funder

National Health and Medical Research Council

Publisher

Wiley

Subject

General Medicine,Histology,Pathology and Forensic Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/his.13498/fullpdf

Reference67 articles.

1. Global cancer in women: burden and trends;Torre;Cancer Epidemiol. Biomarkers Prev.,2017

2. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial;Cameron;Lancet Oncol.,2013

3. Triple-negative breast cancer: current practice and future directions;Costa;J. Oncol. Pract.,2017

4. Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity;Dannenfelser;Oncotarget,2017

5. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer;Burstein;Clin. Cancer Res.,2015

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Immunohistochemical Study of MAGE Proteins in Hepatocellular Carcinoma;Diagnostics;2024-08-05

2. Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies;Cancer Cell;2024-01

3. Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential;Cancers;2023-12-26

4. Development of dendritic cell loaded MAGE-A2 long peptide; a potential target for tumor-specific T cell-mediated prostate cancer immunotherapy;Cancer Cell International;2023-11-11

5. Chimeric antigen receptor‐based immunotherapy in breast cancer: Recent progress in China;Cancer;2023-11-11